Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials.
Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. Recent therapeutic innovations, including the addition of daratumumab to standard regimens, have shown promising improvements in patient outcomes.
Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. Recent therapeutic innovations, including the addition of daratumumab to standard regimens, have shown promising improvements in patient outcomes.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Ther Adv Hematol
Why it surfaced
Matched watchlist topic 'Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)'. Study design: Randomized Controlled Trial (inferred). Score: 9/10 (N:2, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.